

Top 20: INDIA - Marginal growth

04 July 2014 | Analysis | By BioSpectrum Bureau





India's bioscience success story received a jolt in 2013 due to regulatory and pricing issues.

The sector grew only by 3 percent. Interestingly, India too had eight companies that crossed the \$1 billion mark. In fact, India's two leading companies Sun Pharma and Dr Reddy's have touched the \$2 billion mark for the first time.

India announced its plan to elevate its pharma industry to touch \$100 billion by 2020.

USFDA deputed training personnel to Indian state, Gujarat, to enhance quality standards of drugs exported from the state.

GE Healthcare and Cancer Treatment Services International (CTSI) plans to invest \$120 million in India to develop 25 world-class centers across the country to improve cancer care over a period of 5 years.

INDIA: TOP 20 BIOSCIENCE COMPANIES

Rank	Company	Revenue		
		CY 2013 (\$M)	CY 2012 (\$M)	Change over 2012
1	Sun Pharma	2,466.9	1,877.5	31%
2	Dr Reddys Laboratories	2,145.9	1,957.6	10%
3	Ranbaxy Laboratories	1,753.0	2,180.5	-20%
4	Lupin	1,735.0	1,575.3	10%
5	Cipla	1,516.4	1,428.0	6%
6	Aurobindo Pharma	1,195.6	966.0	24%
7	Dabur India	1,121.7	1,069.4	5%
8	Cadila Healthcare	1,101.1	1,061.3	4%
9	Glenmark Pharmaceuticals	925.2	848.3	9%
10	Jubilant Life Sciences	913.2	881.5	4%
11	Wockhardt	866.0	974.7	-11%
12	Piramal Enterprises Limited (Formerly called Piramal Healthcare)	699.9	561.6	25%
13	Torrent Pharma	596.0	519.6	15%
14	Bilcare	525.5	675.1	-22%
15	Ipca Laboratories	508.8	471.0	8%
16	Biocon	453.0	426.9	6%
17	GlaxoSmithKline Pharmaceuticals	413.6	465.0	-11%
18	Divis Laboratories	396.9	390.3	2%
19	Emami (Formerly Zandu Pharma)	299.7	295.4	1%
20	Alembic Pharmaceuticals	291.1	265.0	10%

* Revenue of listed companies only